YOU'RE INVITED TO A ZOOM WEBINAR



PHARMAC TE PĀTAKA WHAIORANGA

WHAT'S NEW WITH TYPE 2 DIABETES CARE IN 2021 THURS, 18TH FE

When and how are SGLT2 inhibitors and GLP1 agonists used?

THURS, 18TH FEBRUARY 1PM - 2PM AND REPEATED ON WED, 24TH FEBRUARY 7PM - 8PM



DR RYAN PAUL

Academic Endocrinologist at Waikato District Health Board and at the University of Waikato

Dr Ryan Paul is an Executive Member of the New Zealand Society for the Study of Diabetes (NZSSD) and recently led the development of the NZSSD guidance on the management of type 2 diabetes in New Zealand. Dr Paul is heavily involved in teaching primary care clinicians, diabetes nurse prescribers and endocrinology trainees.

THE TOPIC WILL INCLUDE:

- The updated treatment algorithm of type 2 diabetes in New Zealand
- When and how to use SGLT2 inhibitors and GLP1 receptor agonists
- Who does and who does not meet the special authority criteria for funded SGLT2 inhibitors and GLP1 receptor agonists
- mobile health
- New recommendations for the screening and management of type 2 diabetes in Aotearoa New Zealand
 - Achieving equity in diabetes outcomes in Aotearoa New Zealand
 - Case discussion

REGISTRATIONS REQUIRED

Lunchtime webinar on the 18th Feb - tinyurl.com/u2m08kg3 Evening webinar on the 24th Feb - tinyurl.com/5c3k4pfb